{"disease":{"id":"severe-atopic-dermatitis","name":"severe atopic dermatitis"},"drugs":{"marketed":[{"drug_id":"upadacitinib","indication_name":"Refractory, moderate to severe atopic dermatitis in adults and pediatric patients 12 years of age and older not adequately controlled with other systemic therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rinvoq","generic_name":"upadacitinib","company_name":"AbbVie Inc.","drug_phase":"marketed","molecular_target":"Janus kinase (JAK) enzymes, particularly JAK1 and JAK2","drug_class":"JAK inhibitor","quality_score":86,"revenue":"5300","mechanism":"JAK inhibitor that prevents STAT phosphorylation and activation in cytokine signaling pathways."},{"drug_id":"abrocitinib-100-mg","indication_name":"Moderate to severe atopic dermatitis in children aged 12 years and older who have had an inadequate response or intolerance to one or more biologics, or who are candidates for systemic therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abrocitinib 100 mg","generic_name":"abrocitinib-100-mg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1","drug_class":"Janus kinase inhibitor","quality_score":48,"revenue":"284","mechanism":""},{"drug_id":"abrocitinib-suspension-f1","indication_name":"Moderate to severe atopic dermatitis in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abrocitinib Suspension F1","generic_name":"abrocitinib-suspension-f1","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1","drug_class":"JAK inhibitor","quality_score":33,"revenue":"284","mechanism":""},{"drug_id":"abrocitinib-suspension-f1","indication_name":"Moderate to severe atopic dermatitis in children 12 years of age and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abrocitinib Suspension F1","generic_name":"abrocitinib-suspension-f1","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1","drug_class":"JAK inhibitor","quality_score":33,"revenue":"284","mechanism":""},{"drug_id":"abrocitinib-suspension-f2","indication_name":"Moderate to severe atopic dermatitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abrocitinib Suspension F2","generic_name":"abrocitinib-suspension-f2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"unknown","quality_score":10,"revenue":"284","mechanism":""},{"drug_id":"abrocitinib-suspension-f6","indication_name":"Moderate to severe atopic dermatitis in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abrocitinib Suspension F6","generic_name":"abrocitinib-suspension-f6","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1","drug_class":"JAK inhibitor","quality_score":40,"revenue":"284","mechanism":""},{"drug_id":"abrocitinib-suspension-f6","indication_name":"Moderate to severe atopic dermatitis in children 12 years of age and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abrocitinib Suspension F6","generic_name":"abrocitinib-suspension-f6","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1","drug_class":"JAK inhibitor","quality_score":40,"revenue":"284","mechanism":""},{"drug_id":"abrocitinib-200-mg","indication_name":"Moderate to severe atopic dermatitis in adults who have had an inadequate response or intolerance to one or more biologics, or who are candidates for systemic therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abrocitinib 200 mg","generic_name":"abrocitinib-200-mg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1","drug_class":"JAK inhibitor","quality_score":40,"revenue":"284","mechanism":""},{"drug_id":"abrocitinib-100-mg","indication_name":"Moderate to severe atopic dermatitis in adults who have had an inadequate response or intolerance to one or more biologics, or who are candidates for systemic therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abrocitinib 100 mg","generic_name":"abrocitinib-100-mg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1","drug_class":"Janus kinase inhibitor","quality_score":48,"revenue":"284","mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe atopic dermatitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe atopic dermatitis and psoriatic arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe atopic dermatitis and ankylosing spondylitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe atopic dermatitis and Crohn's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe atopic dermatitis and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe atopic dermatitis and hidradenitis suppurativa","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"induction-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to Severe Atopic Dermatitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 150 mg SC Q4W","generic_name":"induction-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks."},{"drug_id":"tralokinumab","indication_name":"Moderate to severe atopic dermatitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Adbry","generic_name":"TRALOKINUMAB","company_name":"Leo Pharma As","drug_phase":"marketed","molecular_target":"Interleukin-13","drug_class":"Interleukin-13 Antagonist [EPC]","quality_score":10,"revenue":null,"mechanism":"Adbry blocks the action of IL-13, a protein that contributes to inflammation and skin barrier disruption in atopic dermatitis."},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe atopic dermatitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe atopic dermatitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriasis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, rheumatoid arthritis, hidradenitis suppurativa, and atopic dermatitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriasis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, rheumatoid arthritis, hidradenitis suppurativa, atopic dermatitis, and plaque psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-450-mg-sc-q4w","indication_name":"Moderate to severe atopic dermatitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 450 mg SC Q4W","generic_name":"chronic-pf-06480605-450-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"IL-4 receptor alpha subunit","drug_class":"pharmacological class not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-450-mg-sc-q4w","indication_name":"Moderate to severe atopic dermatitis in infants and children","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 450 mg SC Q4W","generic_name":"chronic-pf-06480605-450-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"IL-4 receptor alpha subunit","drug_class":"pharmacological class not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"lebrikizumab","indication_name":"moderate-to-severe atopic dermatitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ebglyss","generic_name":"LEBRIKIZUMAB","company_name":"Eli Lilly And Co","drug_phase":"marketed","molecular_target":"","drug_class":"Interleukin-13 Antagonist [EPC]","quality_score":10,"revenue":null,"mechanism":"Ebglyss works by binding to interleukin-13, a protein that promotes inflammation in the skin."},{"drug_id":"lebrikizumab","indication_name":"Moderate-to-severe atopic dermatitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ebglyss","generic_name":"LEBRIKIZUMAB","company_name":"Eli Lilly And Co","drug_phase":"marketed","molecular_target":"","drug_class":"Interleukin-13 Antagonist [EPC]","quality_score":10,"revenue":null,"mechanism":"Ebglyss works by binding to interleukin-13, a protein that promotes inflammation in the skin."},{"drug_id":"lebrikizumab","indication_name":"moderate-to-severe atopic dermatitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ebglyss","generic_name":"LEBRIKIZUMAB","company_name":"Eli Lilly And Co","drug_phase":"marketed","molecular_target":"","drug_class":"Interleukin-13 Antagonist [EPC]","quality_score":10,"revenue":null,"mechanism":"Ebglyss works by binding to interleukin-13, a protein that promotes inflammation in the skin."},{"drug_id":"chembl-chembl3655081","indication_name":"Refractory, moderate-to-severe atopic dermatitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"ABROCITINIB","company_name":"","drug_phase":"marketed","molecular_target":"JAK1","drug_class":"Janus Kinase Inhibitor [EPC]","quality_score":55,"revenue":null,"mechanism":"CIBINQO works by reversibly inhibiting JAK1, blocking ATP binding and showing selectivity over other JAKs."},{"drug_id":"induction-pf-06480605-450-mg-sc-q4w","indication_name":"Moderate to severe atopic dermatitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 450 mg SC Q4W","generic_name":"induction-pf-06480605-450-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"IL-17 receptor","drug_class":"small molecule","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a small molecule that targets the IL-17 pathway to treat inflammatory conditions."},{"drug_id":"induction-pf-06480605-450-mg-sc-q4w","indication_name":"Moderate to severe Crohn's disease and perianal disease and fistulizing disease and axial involvement and psoriatic arthritis and atopic dermatitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 450 mg SC Q4W","generic_name":"induction-pf-06480605-450-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"IL-17 receptor","drug_class":"small molecule","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a small molecule that targets the IL-17 pathway to treat inflammatory conditions."},{"drug_id":"induction-pf-06480605-450-mg-sc-q4w","indication_name":"Moderate to severe ulcerative colitis and perianal disease and fistulizing disease and axial involvement and psoriatic arthritis and atopic dermatitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 450 mg SC Q4W","generic_name":"induction-pf-06480605-450-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"IL-17 receptor","drug_class":"small molecule","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a small molecule that targets the IL-17 pathway to treat inflammatory conditions."},{"drug_id":"induction-pf-06480605-450-mg-sc-q4w","indication_name":"Moderate to severe Crohn's disease and perianal disease and fistulizing disease and axial involvement and psoriatic arthritis and atopic dermatitis and hidradenitis suppurativa","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 450 mg SC Q4W","generic_name":"induction-pf-06480605-450-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"IL-17 receptor","drug_class":"small molecule","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a small molecule that targets the IL-17 pathway to treat inflammatory conditions."},{"drug_id":"induction-pf-06480605-450-mg-sc-q4w","indication_name":"Moderate to severe ulcerative colitis and perianal disease and fistulizing disease and axial involvement and psoriatic arthritis and atopic dermatitis and hidradenitis suppurativa","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 450 mg SC Q4W","generic_name":"induction-pf-06480605-450-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"IL-17 receptor","drug_class":"small molecule","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a small molecule that targets the IL-17 pathway to treat inflammatory conditions."},{"drug_id":"induction-pf-06480605-450-mg-sc-q4w","indication_name":"Moderate to severe Crohn's disease and perianal disease and fistulizing disease and axial involvement and psoriatic arthritis and atopic dermatitis and hidradenitis suppurativa and psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 450 mg SC Q4W","generic_name":"induction-pf-06480605-450-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"IL-17 receptor","drug_class":"small molecule","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a small molecule that targets the IL-17 pathway to treat inflammatory conditions."},{"drug_id":"induction-pf-06480605-450-mg-sc-q4w","indication_name":"Moderate to severe ulcerative colitis and perianal disease and fistulizing disease and axial involvement and psoriatic arthritis and atopic dermatitis and hidradenitis suppurativa and psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 450 mg SC Q4W","generic_name":"induction-pf-06480605-450-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"IL-17 receptor","drug_class":"small molecule","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a small molecule that targets the IL-17 pathway to treat inflammatory conditions."}],"pipeline":[],"offLabel":[],"totalMarketed":34,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03057860","title":"TREATgermany: German National Clinical Registry for Patients With Moderate-to-severe Atopic Dermatitis","phase":"","overall_status":"RECRUITING","enrollment_count":2800,"lead_sponsor_name":"Technische Universität Dresden","has_results":false},{"nct_id":"NCT03989206","title":"Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1700,"lead_sponsor_name":"Galderma R&D","has_results":false},{"nct_id":"NCT03985943","title":"Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":941,"lead_sponsor_name":"Galderma R&D","has_results":true},{"nct_id":"NCT03989349","title":"Efficacy & Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":787,"lead_sponsor_name":"Galderma R&D","has_results":true},{"nct_id":"NCT06468956","title":"Efficacy and Safety Study of SHR-1819 Injection in Adult Patients With Severe Atopic Dermatitis","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":652,"lead_sponsor_name":"Guangdong Hengrui Pharmaceutical Co., Ltd","has_results":false},{"nct_id":"NCT06723080","title":"Phase III Clinical Study of VC005 Tablets in Adult Patients With Moderate to Severe Atopic Dermatitis","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":480,"lead_sponsor_name":"Jiangsu vcare pharmaceutical technology co., LTD","has_results":false},{"nct_id":"NCT07370909","title":"Evaluation of the Efficacy and Safety of Oral LW402 Tablets for the Treatment of Patients With Moderate-to-Severe Atopic Dermatitis","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":480,"lead_sponsor_name":"Shanghai Longwood Biopharmaceuticals Co., Ltd.","has_results":false},{"nct_id":"NCT03568162","title":"Phase 2b Study to Evaluate the Efficacy and Safety of ISB 830 in Adults With Moderate to Severe Atopic Dermatitis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":462,"lead_sponsor_name":"Ichnos Sciences SA","has_results":true},{"nct_id":"NCT06136741","title":"A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":396,"lead_sponsor_name":"Nektar Therapeutics","has_results":false},{"nct_id":"NCT05017480","title":"A Study to Evaluate the Efficacy and Safety of CBP-201 in Moderate to Severe Atopic Dermatitis in China","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":330,"lead_sponsor_name":"Connect Biopharm LLC","has_results":true},{"nct_id":"NCT06099704","title":"Observational Study of Canadian Patients (6 Years or Older) Receiving Dupixent® for Moderate to Severe Atopic Dermatitis","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":305,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT03054428","title":"Efficacy and Safety of Dupilumab in Participants ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":251,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":true},{"nct_id":"NCT05671432","title":"The Study of CM326 in Moderate-to-severe Atopic Dermatitis","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":240,"lead_sponsor_name":"Keymed Biosciences Co.Ltd","has_results":false},{"nct_id":"NCT04444752","title":"A Study to Assess the Efficacy and Safety of CBP-201 in Adult Subjects With Moderate to Severe Atopic Dermatitis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":226,"lead_sponsor_name":"Connect Biopharm LLC","has_results":true},{"nct_id":"NCT05899816","title":"A Study Assessing Rocatinlimab on Vaccine Antibody Response in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET - VOYAGER)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":221,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT07465120","title":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase Ⅱ Clinical Study to Evaluate the Efficacy and Safety of CMS-D001 in Adult Patients With Moderate to Severe Atopic Dermatitis","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":160,"lead_sponsor_name":"Dermavon Holdings Limited","has_results":false},{"nct_id":"NCT05549947","title":"Efficacy and Safety Study of SHR-1819 Injection in Adult Patients With Severe Atopic Dermatitis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":158,"lead_sponsor_name":"Shanghai Hengrui Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT05997927","title":"Efficacy and Safety Clinical Study of VC005 Tablets in Adult Patients With Moderate to Severe Atopic Dermatitis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":149,"lead_sponsor_name":"Jiangsu vcare pharmaceutical technology co., LTD","has_results":false},{"nct_id":"NCT04417894","title":"A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Moderate-to-Severe Atopic Hand and Foot Dermatitis (Liberty-AD-HAFT)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":133,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":true},{"nct_id":"NCT04893707","title":"The Study of CM310 in Patients With Atopic Dermatitis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":127,"lead_sponsor_name":"Keymed Biosciences Co.Ltd","has_results":false},{"nct_id":"NCT05590585","title":"Dupilumab in Adolescent and Adult Skin of Color Participants: Open-label Moderate-to-severe Eczema Trial","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":124,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":true},{"nct_id":"NCT06158490","title":"A Study to Evaluate JYP0061 Tablets in Patients With Moderate-to-severe Atopic Dermatitis","phase":"PHASE2","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":120,"lead_sponsor_name":"Guangzhou JOYO Pharma Co., Ltd","has_results":false},{"nct_id":"NCT04805411","title":"Subcutaneously CM310/Placebo in Patients With Moderate-to-Severe Atopic Dermatitis (AD)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":120,"lead_sponsor_name":"Keymed Biosciences Co.Ltd","has_results":false},{"nct_id":"NCT06934252","title":"Phase 1a/1b Study of TRB-061 in Healthy Participants & Atopic Dermatitis Patients","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":115,"lead_sponsor_name":"TRex Bio, Inc.","has_results":false},{"nct_id":"NCT04921345","title":"Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants With Moderate-to-Severe Atopic Dermatitis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":105,"lead_sponsor_name":"Galderma R&D","has_results":false},{"nct_id":"NCT06012812","title":"A Study to Extend Efficacy and Safety of SHR-1819 Injection in Adult Patients With Moderate to Severe Atopic Dermatitis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":79,"lead_sponsor_name":"Shanghai Hengrui Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT03052348","title":"Efficacy of Combining Topical Antibiotic/Steroid/Moisturizer Therapy Compared to Active Comparator in Atopic Dermatitis.","phase":"NA","overall_status":"UNKNOWN","enrollment_count":78,"lead_sponsor_name":"Red Cross War Memorial Childrens Hospital","has_results":false},{"nct_id":"NCT05702268","title":"Pharmacodynamic Blood Characteristics of ICP-332 in Patients With Moderate to Severe Atopic Dermatitis","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":75,"lead_sponsor_name":"Beijing InnoCare Pharma Tech Co., Ltd.","has_results":false},{"nct_id":"NCT05203380","title":"Neuropsychologic Assessments of Dupilumab-Treated Adolescent Participants With Moderate-to-Severe Atopic Dermatitis","phase":"","overall_status":"COMPLETED","enrollment_count":45,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false},{"nct_id":"NCT04893941","title":"Dose Escalation Trial of CM310 in Patients With Moderate-to-Severe Atopic Dermatitis (AD)","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":39,"lead_sponsor_name":"Keymed Biosciences Co.Ltd","has_results":false},{"nct_id":"NCT05984784","title":"A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of IMG-007 in Adults With Atopic Dermatitis (AD)","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":13,"lead_sponsor_name":"Inmagene LLC","has_results":true},{"nct_id":"NCT07187089","title":"Study of Growth and Bone Mineral Density in Children With Atopic Dermatitis (AD) Treated With Dupilumab","phase":"PHASE4","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false},{"nct_id":"NCT05466578","title":"Pre-approval Single-patient Expanded Access for Abrocitinib (PF-04965842)","phase":"","overall_status":"AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Pfizer","has_results":false}],"total":33},"guidelines":[],"source":"Drug Landscape verified database"}